



Evolut Clinical Guideline 2001 for Abdomen Computed Tomography (CT)

Guideline Number: Evolut_CG_2001	<u>Applicable Codes</u>	
<i>"Evolut" refers to Evolut Health LLC and Evolut Specialty Services, Inc.</i> © 1997 - 2026 Evolut. All rights Reserved.		
Original Date: September 1997	Last Revised Date: July 2025	Implementation Date: January 2026

TABLE OF CONTENTS

STATEMENT	3
GENERAL INFORMATION.....	3
PURPOSE.....	3
SPECIAL NOTE.....	3
INDICATIONS FOR ABDOMEN CT	3
ORGAN SPECIFIC IMAGING	3
<i>Adrenal</i>	3
<i>Liver</i>	4
<i>Pancreas</i>	4
<i>Renal</i>	5
<i>Spleen</i>	6
<i>Endocrine Disorders</i>	6
EVALUATION OF INFECTION AND INFLAMMATION.....	7
<i>Pancreatitis: Suspected and Known</i>	7
<i>Infection and Inflammation Limited to the Abdomen</i>	7
HERNIA.....	7
OTHER INDICATIONS.....	8
KNOWN MALIGNANCY	8
<i>Initial Staging or Recurrence</i>	8
<i>Restaging</i>	9
<i>Surveillance</i>	9
PREOPERATIVE OR POSTOPERATIVE ASSESSMENT	9
FURTHER EVALUATION OF INDETERMINATE FINDINGS.....	10
IMAGING IN KNOWN GENETIC CONDITIONS	10
SURVEILLANCE SCREENING	10
SCREENING BASED ON KNOWN GENETIC SYNDROME IN COMBINATION WITH FAMILY HISTORY	11
SURVEILLANCE SCREENING BASED ON FAMILY HISTORY	11
SPECIAL NOTE.....	12
OTHER COMBINATION STUDIES WITH ABDOMEN CT	12
ABDOMEN CT AND ABDOMEN CTA (OR MRA).....	12

ABDOMEN/SINUS/MAXILLOFACIAL/NECK/CHEST CT	12
ABDOMEN CT AND ABDOMEN CTA (OR MRA) AND PET	12
COMBINATION STUDIES FOR MALIGNANCY FOR INITIAL STAGING OR RESTAGING	12
CODING AND STANDARDS	13
CODES	13
APPLICABLE LINES OF BUSINESS	13
BACKGROUND	13
CONTRAINDICATIONS AND PREFERRED STUDIES	13
SUMMARY OF EVIDENCE	13
ANALYSIS OF EVIDENCE	15
POLICY HISTORY	15
LEGAL AND COMPLIANCE	16
GUIDELINE APPROVAL	16
<i>Committee</i>	17
DISCLAIMER	17
REFERENCES.....	18

STATEMENT

General Information

- *It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. If applicable: All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.*
- *Where a specific clinical indication is not directly addressed in this guideline, medical necessity determination will be made based on widely accepted standard of care criteria. These criteria are supported by evidence-based or peer-reviewed sources such as medical literature, societal guidelines and state/national recommendations.*
- *The guideline criteria in the following sections were developed utilizing evidence-based and peer-reviewed resources from medical publications and societal organization guidelines as well as from widely accepted standard of care, best practice recommendations.*

Purpose

Abdomen Computed Tomography (CT) uses radiation to generate images of the organs and structures in the upper abdomen. Abdominal imaging begins at the diaphragm and extends to the umbilicus or iliac crests.

Special Note

- Abdomen CT is used for diseases suspected to be limited to the abdomen. Abdomen and Pelvis CT (CPT Codes: 74176, 74177, 74178) is used when the indication(s) include both the abdomen **AND** pelvis, such as CT Urography, CT Enterography, acute abdominal pain or widespread inflammatory disease.
- When separate requests for CT abdomen and CT Pelvis are encountered for processes involving both the abdomen and pelvis, they need to be resubmitted as Evolent Clinical Guideline 2000 for Abdomen and Pelvis CT (to avoid unbundling; CPT codes 74176, 74177, 74178).

INDICATIONS FOR ABDOMEN CT

Organ Specific Imaging

Adrenal ⁽¹⁾

- Indeterminate adrenal lesion seen on prior imaging
- For follow up of known adrenal mass when a change in tumor is suspected by either imaging, laboratory evaluation and/or symptoms
- Adrenal mass < 4 cm incidentally discovered with benign characteristics (homogenous,

regular borders, HU < 10), one follow-up at 6 months then annually x 2 years (no further imaging if stable) ⁽²⁾

- Adrenal mass ≥ 4 cm and no diagnosis of cancer, can approve for either pre-operative planning **OR** if surgery is not done, repeat imaging in 6-12 months then as clinically indicated (if there is known malignancy, biopsy is typically the next step rather than surveillance imaging) ⁽²⁾
- See **Endocrine Disorders** for additional indications
- See **Imaging in Known Genetic Conditions** for additional screening indications

Liver

- Indeterminate liver lesion seen on prior imaging ⁽³⁾
- Elevated or rising AFP in patients at high risk for Hepatocellular Carcinoma (HCC) (known cirrhosis and/or chronic hepatitis B, Asian male Hepatitis B carriers ≥ 40 y, Asian female Hepatitis B carriers ≥ 50 y, Hepatitis B carriers with + family history of HCC and African and/or North American blacks with hepatitis B) ⁽⁴⁾
- Screening in patients at high risk for HCC (see above) every 6 months when prior ultrasound is insufficient to evaluate the liver due to steatosis/fatty liver or nodular liver
 - The finding of steatosis/fatty liver and/or nodular liver alone on an ultrasound report is insufficient; the report must specify that those findings prevent adequate visualization of the liver by ultrasound
- Jaundice or abnormal liver function tests after equivocal or abnormal ultrasound ⁽⁵⁾
- Follow-up of suspected hepatocellular adenomas every 6-12 months for two years, then annually (sooner if change was noted on last imaging study) ^(6,7)
- Surveillance of patients with primary sclerosing cholangitis every 6-12 months after the age of 20 when MRI is contraindicated or cannot be performed ⁽⁸⁾
- Follow-up of focal nodular hyperplasia (FNH), repeat imaging in 6-12 months to ensure stability. Additional imaging beyond that is needed only if atypical features or diagnosis is still in question ⁽⁶⁾
- See **Imaging in Known Genetic Conditions** for additional screening indications

Pancreas

- Pancreatic cystic lesion found on initial imaging for characterization of lesion ⁽⁹⁾
- Follow-up for pancreatic cyst (including Intraductal Papillary Mucinous Neoplasm (IPMN)) as below **AND** MRI is contraindicated ^(10,11):
 - Incidental and asymptomatic cysts <1.5 cm, **AND**:
 - Age < 65, image annually x 5 years, then every 2 years if stable
 - Age 65-79, imaging every 2 years x 5, then stop if stable
 - Cysts 1.5-1.9 cm with main pancreatic duct communication (MPD), image annually x

- 5 years, then every 2 years x 2, stop if stable at year 9
- Cysts 2.0-2.5 cm with MPD communication, image every 6 months x 4, then annually x 2, then every 2 years x 3, stop if stable at year 10
- Cysts 1.5-2.5 cm with **NO** MPD communication (or cannot be determined), image every 6 mos. x 4, then annually x 2 then every 2 years x 3, stop if stable at year 10
- Cyst > 2.5 cm on surveillance (i.e., intervention has not been chosen), image every 6 mos. x 4, then annually x 2 years, then every 2 years x 3. Stop if stable at year 10
- Patients > 80 years of age at presentation are imaged less frequently: image every 2 years x 2, stop if stable at year 4 (intervals are the same regardless of size if surveillance chosen)
- Growth or suspicious change on a surveillance imaging scan may warrant more frequent surveillance
- Prior to Y90 treatment
- After confirmed diagnosis of exocrine pancreatic insufficiency (EPI), one-time imaging to exclude a secondary cause for EPI. (Imaging is not indicated for workup of suspected pancreatic insufficiency; fecal elastase level < 100 µg/g is consistent with EPI) ⁽¹²⁾
- See **Endocrine Disorders** for additional indications
- See **Genetic Syndromes and Rare Diseases** for additional screening indications

Renal

- Indeterminate renal mass on other imaging ⁽¹³⁾
- Active surveillance for a solid renal mass(es) at 6 and 12 months, then annually ⁽¹⁴⁾
NOTE: more frequent imaging may be indicated if a change in the mass was seen
- Active surveillance for follow-up of a Bosniak IIF, III and IV complex cystic renal lesion(s) ^(15,16):
 - Every 6 months for the first year then
 - Annually for 5 years if no progression
 - If progression or change is seen, then follow-up imaging may be indicated prior to the above intervals.
 - **NOTE:** Bosniak I and II cysts need no further follow-up. (Bosniak I cysts are simple non-enhancing cysts with thin walls, no septa, calcifications or solid components, Bosniak II cysts may contain thin septa, small or fine calcification, minimal enhancement and/or hyperdense and < 3 cm) ⁽¹⁷⁾
- Surveillance of known angiomyolipoma (AML) ⁽¹⁸⁻²⁰⁾:
 - Size > 4 cm: Annually
 - Size 3-4 cm: Every 2 years
 - **NOTE:** if < 3 cm monitoring with advanced imaging (CT/MRI) is not needed unless the pt has known Tuberous Sclerosis ^(19,21)

- AML (any size) in an individual with known tuberous sclerosis (TSC): Annually (including at diagnosis) ^(14,20)
- Post-embolization imaging for AML:
 - One study within the first 6 months, then
 - At one-year post-embolization
 - If stable, further imaging reverts to the above imaging frequency for monitoring (based on size and/or presence of known TSC) ^(22,23)
- See **Genetic Syndromes and Rare Diseases** for additional screening indications

Spleen

- Incidental findings of the spleen that are indeterminate on other imaging ^(24,25)
- See **Imaging in Known Genetic Conditions** for additional screening indications

Endocrine Disorders ⁽²⁾

- For further evaluation of suspected adrenal tumors and/or endocrine disorders when there is clinical and laboratory evidence to suggest an abdominal source ⁽²⁶⁾
 - Suspected adrenocortical carcinoma
 - Elevated adrenal androgens (DHEA-S, androstenedione, testosterone, 17-hydroxyprogesterone)
 - Cushing's Syndrome:
 - ACTH < 5 following dexamethasone suppression
 - ACTH 5-20 (i.e. indeterminate) with CRH/desmopressin stimulation test and ACTH < 5 (post-stimulation)
 - Hyperaldosteronism: Aldosterone > 20 (or Aldosterone: Renin ratio > 20) and Low Plasma Renin Activity
 - Gastrinoma: Elevated serum gastrin
 - GI Carcinoid: Elevated 24-hour urine 5-HIAA or elevated plasma 5-HIAA
 - Glucagonoma: Elevated serum glucagon
 - Hypoglycemia: One of the following:
 - Elevated serum insulin, pro-insulin and c-peptide **ALL** drawn during a period of hypoglycemia (72 hour fast) (i.e. concern for insulinoma)
 - Low serum insulin, low C-peptide and/or elevated IGF-2:IGF-1 ratio
 - Hypercalcemia: Elevated serum calcium, low-normal PTH, high PTHrP **AND** bone imaging (bone scan) does not reveal a source
 - Insulinoma: Elevated serum insulin, pro-insulin and c-peptide **ALL** drawn during a period of hypoglycemia (72 hour fast)
 - Pheochromocytoma/Paraganglioma: Elevated plasma or urine metanephrines and/or

- normetanephrines
- PPoma: Elevated serum pancreatic polypeptide
- Somatostatinoma: Elevated serum somatostatin
- VIPoma: Elevated serum VIP

Evaluation of Infection and Inflammation

Pancreatitis: Suspected and Known ⁽²⁷⁾

- Initial imaging for suspected acute pancreatitis due to epigastric pain with elevated amylase and/or lipase ⁽²⁸⁾:
 - For mild presentation when symptom improvement is not seen after 72 hours of treatment and either:
 - Ultrasound has been performed and did not show an abnormality such as gallstones, dilated bile duct
 - Ultrasound suggests complications (such as fluid collection)
 - For severe presentation (such as fever, elevated WBC)
 - For a decline in clinical status and/or suspected complication
- History of pancreatitis, including pancreatic pseudocyst, with abdominal pain suspicious for worsening or re-exacerbation
- Known necrotizing pancreatitis requiring follow-up ⁽²⁸⁾
- In patients > 40 years of age who have pancreatitis with no identifiable cause (to exclude neoplasm)

Infection and Inflammation Limited to the Abdomen ^(27,29)

- Any known infection that is clinically suspected to have created an abscess limited to the abdomen (If location unclear or unknown, CT Abdomen/Pelvis is more appropriate)
- Any history of fistula limited to the abdomen that requires re-evaluation or is suspected to have recurred
- Abnormal fluid collection limited to the abdomen seen on prior imaging that needs follow-up evaluation

Hernia ⁽³⁰⁾

- Suspected hernia and one of the following:
 - Deep intraabdominal/pelvic hernia (post-Roux-en-Y)
 - Non-midline ventral hernia (including Spigelian hernia) ⁽³¹⁾
 - Parastomal hernia
 - Occult, incisional, recurrent or umbilical hernia **AND** exam and ultrasound are non-

diagnostic or equivocal

- Known or suspected hernia with suspected complications based on one or more of the following:
 - Symptoms such as severe pain, vomiting, diarrhea or blood in stool
 - Exam findings such as inability to reduce hernia, severe tenderness, guarding, rebound
 - Complication is suggested on prior imaging ⁽³¹⁾
- Known or suspected Diaphragmatic hernia (e.g. Bochdalek, Morgagni or congenital) or large type IV hiatal hernia ^(32,33)
- Known lower esophageal hernia (such as type II or III hiatal or paraesophageal) and imaging is needed for Surgical planning
- Known abdominal hernia and imaging is needed for surgical planning

Other Indications

- Right upper quadrant pain for suspected biliary disease with negative or equivocal ultrasound ⁽³⁴⁾
- Evaluation of known or suspected non-aortic vascular disease (such as aneurysm, hematomas) after inconclusive ultrasound **AND** CTA/MRA is contraindicated or cannot be performed ⁽³⁵⁾
- Prior to solid organ transplantation
- For abnormal incidental abdominal lymph nodes when follow-up is recommended based on prior imaging and pelvic imaging is not needed (initial 3-month follow-up) ⁽³⁶⁾

Known Malignancy ^(37,38)

Initial Staging or Recurrence

- For initial staging of the majority of cancers, CT Abdomen and Pelvis is the more appropriate study (see Evolent Clinical Guideline 2000 for Abdomen and Pelvis CT).
- Abdomen CT is indicated for initial staging for the following malignancies:
 - Any malignancy with known or suspected liver metastases (i.e. dedicated liver imaging for metastases) ⁽³⁹⁾
 - Esophageal and Esophagogastric Junction Cancers ⁽⁴⁰⁾
 - Melanoma: Uveal ⁽⁴¹⁾
 - Pancreatic Cancer ⁽¹⁴⁾
 - Primary Liver Cancers ⁽⁴²⁾
 - Renal Cell Carcinoma ⁽¹⁴⁾

Restaging

- Abdomen CT is indicated for restaging during active treatment (every 2-3 cycles of chemo or immunotherapy, following radiation and/or after surgery) for the following malignancies:
 - Any malignancy with known or suspected liver metastases (i.e. dedicated liver imaging for metastases) ⁽³⁹⁾
 - Esophageal and Esophagogastric Junction Cancers ⁽⁴⁰⁾
 - Melanoma: Uveal ⁽⁴¹⁾
 - Pancreatic Cancer ⁽⁴³⁾
 - Primary Liver Cancers ⁽³⁹⁾
 - Renal Cell Carcinoma ⁽¹⁴⁾

Surveillance

Abdomen CT is indicated during surveillance for the following malignancies at the intervals defined below:

- Any malignancy with a history of liver metastases: every 3-6 months ⁽³⁹⁾
- Esophageal and Esophagogastric Junction Cancers every 3 months for 2 years, then annually for 5 years ⁽⁴⁰⁾
- Hepatocellular Carcinoma every 3 months for 2 years, then every 6 months indefinitely ⁽³⁹⁾
- Melanoma: Uveal - every 6-12 months for 10 years then as clinically indicated ⁽⁴¹⁾
- Renal Cell Carcinoma ⁽¹⁴⁾
 - Stage I – 1-3 months after treatment, then at 6 months and 12 months following treatment then annually
 - Stage II and higher- every 3-6 months for 3 years, then annually for 2 years, then as clinically indicated
- When a cancer is not listed above, Abdomen CT is not routinely a part of surveillance for that cancer in an asymptomatic patient. Please see Evolent Clinical Guideline 2000 for Abdomen and Pelvis CT for additional indications.

PREOPERATIVE OR POSTOPERATIVE ASSESSMENT

When not otherwise specified in the guideline:

Preoperative Evaluation:

- Pre-procedure for transjugular intrahepatic portosystemic shunt (TIPS) ⁽⁴⁴⁾
- Imaging of the area is requested is needed to develop a surgical plan

Postoperative Evaluation:

- Follow-up of known or suspected post-operative complication involving only the abdomen ⁽⁴⁵⁾
- A follow-up study to help evaluate a patient's progress after treatment, procedure, intervention, or surgery. Documentation requires a medical reason that clearly indicates why additional imaging is needed ⁽⁴⁵⁾
- Known or suspected complications
- A clinical reason is provided how imaging may change management

NOTE: This section applies only within the first few months following surgery

FURTHER EVALUATION OF INDETERMINATE FINDINGS

Unless follow-up is otherwise specified within the guideline:

- For initial evaluation of an inconclusive finding on a prior imaging report that requires further clarification **AND** finding is expected to be limited to the abdomen
- One follow-up exam of a prior indeterminate MR/CT finding to ensure no suspicious interval change has occurred. (No further surveillance unless specified as highly suspicious or change was found on last follow-up exam)

IMAGING IN KNOWN GENETIC CONDITIONS

Surveillance Screening:

- ADPKD (Autosomal Dominant Polycystic Kidney Disease): annually (including at diagnosis or prior to treatment) ^(46,47)
- ATM: Annually starting at age 50 (or 10 years younger than the earliest pancreatic cancer diagnosis in the family, whichever is earlier) when MRI is contraindicated or cannot be performed ⁽⁴⁸⁾
- BAP1-TPDS (BAP-1 tumor predisposition syndrome) every 2 years starting at age 30 ^(14,49)
- Beckwith-Wiedemann syndrome: when ultrasound is abnormal or AFP is rising ⁽⁵⁰⁾
- Beta-Thalassemia: annually when MRI is contraindicated or cannot be performed ⁽⁵¹⁾
- BHDS (Birt-Hogg-Dube): annually starting at age 20 (or earlier with family history of renal tumors diagnosed before age 30) ^(14,52)
- BRCA2: annually starting at age 50 (or 10 years younger than the earliest pancreatic cancer diagnosis in the family, whichever is earlier) ^(43,53)

- CDKN2A: annually starting at age 40 (or 10 years younger than the earliest pancreatic cancer diagnosis in the family, whichever is earlier) ⁽⁴⁸⁾
- Gaucher Disease: annually (including at diagnosis) when MRI is contraindicated or cannot be performed ⁽⁵⁴⁾
- Hemochromatosis: at diagnosis when MRI is contraindicated or cannot be performed ⁽⁵⁵⁾
- HLRCC (hereditary leiomyomatosis and renal cell cancer) annually starting at age 8 ^(14,56)
- HPRC (hereditary papillary renal carcinoma): annually starting at age 30 ⁽¹⁴⁾
- Multiple Endocrine Neoplasia type 1 (MEN1): annually starting at age 8 ^(57,58)
- Multiple Endocrine Neoplasia type 2 (MEN2): with abnormal biochemical results suggestive of adrenal tumor ⁽⁵⁹⁾
- Hereditary PGL/PCC Syndromes (including SDHx mutations): every 2 years including at diagnosis ^(14,60)
- PRSS1 (Hereditary Pancreatitis; including PRSS1, SPINK1 and other hereditary pancreatitis genes): annually starting 20 years after onset of pancreatitis, or at age 40 years, whichever is earlier when MRI is contraindicated or cannot be performed ⁽⁴⁸⁾
- PTEN: every 2 years (including at diagnosis) starting at age 40 (or 10 years younger than the earliest renal cell cancer diagnosis in the family, whichever is earlier) ⁽⁶¹⁾
- Sickle Cell Disease: annually and MRI is contraindicated or cannot be performed ⁽⁶²⁾
- SKT11 (including Peutz-Jeghers): at diagnosis, annually starting at age 8 ⁽⁶³⁾
- Tuberous sclerosis: annually (including at diagnosis) ^(14,20)
- Von Hippel-Lindau (VHL): annually (including at diagnosis) starting at age 11 ⁽⁶⁴⁾
- For other syndromes and rare diseases not otherwise addressed in the guideline, coverage is based on a case-by-case basis using societal guidance

Screening Based on Known Genetic Syndrome in combination with Family History:

- Known mutation in other pancreatic susceptibility genes (BRCA1, MLH1 (Lynch), MSH2, MSH6, EPCAM, PALB2, TP53 (Li-Fraumeni)) **AND** ≥ 1 first- or second-degree relative with history of pancreatic cancer from the same side of the family as the identified variant: Annually when MRI is contraindicated or cannot be performed starting at age 50 (or 10 years younger than the earliest pancreatic cancer diagnosis in the family, whichever is earlier)

Surveillance Screening Based on Family History

- To Screen for Pancreatic Cancer in patients with no identified mutation listed above **AND** the following family history when MRI is contraindicated or cannot be performed:
 - ≥ 2 first-degree relatives with a history of pancreatic cancer from the same side of the family: Annually

- ≥ 3 first- and/or second-degree relatives with a history of pancreatic cancer from the same side of the family: Annually

Special Note

- For syndromes for which imaging starts in the pediatric age group, MRI is preferred to limit lifetime radiation exposure. When CT is requested instead of MRI, a contraindication or relative contraindication to MRI should be provided such as contraindication to sedation if sedation is required for MRI.

OTHER COMBINATION STUDIES WITH ABDOMEN CT

NOTE: When medical necessity is met for an individual study **AND** conscious sedation is required (such as for young pediatric patients or patients with significant developmental delay), the entire combination is indicated)

Abdomen CT and Abdomen CTA (or MRA)

- When needed for clarification of vascular involvement from tumor (including renal vein thrombosis)

Abdomen/Sinus/Maxillofacial/Neck/Chest CT

- Advanced imaging for Granulomatosis with Polyangiitis (GPA) (formally Wegener's Granulomatosis) ⁽⁶⁵⁾
 - Suspected GPA based on clinical findings (such as biopsy results, lab testing including antineutrophil cytoplasmic antibodies (ANCA))
 - Known GPA when imaging results of a specific anatomic area are needed to guide systemic therapy

Abdomen CT and Abdomen CTA (or MRA) and PET

- Prior to Y90 treatment ⁽⁶⁶⁾

Combination Studies for Malignancy for Initial Staging or Restaging

Unless otherwise specified in this guideline, indication for combination studies for malignancy for initial staging or restaging:

- Concurrent studies to include CT or MRI of any of the following areas as appropriate depending on the cancer: Abdomen, Brain, Chest, Neck, Pelvis, Cervical Spine, Thoracic Spine or Lumbar Spine.

CODING AND STANDARDS

Codes

74150, 74160, 74170, +0722T

Applicable Lines of Business

☒	CHIP (Children’s Health Insurance Program)
☒	Commercial
☒	Exchange/Marketplace
☒	Medicaid
☒	Medicare Advantage

BACKGROUND

Contraindications and Preferred Studies

- Contraindications and reasons why a CT/CTA cannot be performed may include: impaired renal function, significant allergy to IV contrast, pregnancy (depending on trimester)
- Contraindications and reasons why an MRI/MRA cannot be performed may include: impaired renal function, claustrophobia, non-MRI compatible devices (such as non-compatible defibrillator or pacemaker), metallic fragments in a high-risk location, patient exceeds weight limit/dimensions of MRI machine
- Abdominal ultrasound may be limited by the body habitus and BMI (Body Mass Index) and when the abdominal wall thickness impairs visualization of the intra-abdominal contents by ultrasound, CT can be considered without prior ultrasound provided the other guideline criteria for that indication are met

SUMMARY OF EVIDENCE

Diseases of the Abdomen and Pelvis 2018-2021 ⁽¹⁾

Study Design: This chapter provides an overview of adrenal imaging, focusing on the evaluation and management of adrenal masses in various clinical scenarios.

Target Population: Patients with adrenal masses, including those with known biochemical abnormalities, underlying malignancies, or incidental findings.

Key Factors: The document discusses different imaging techniques to differentiate benign from malignant adrenal masses and provides recommended imaging algorithms for the workup of incidental adrenal masses.

Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases ⁽⁷⁾

Study Design: This practice guidance document provides a data-supported approach to the diagnosis, staging, and treatment of hepatocellular carcinoma (HCC), developed by a panel of experts.

Target Population: Patients diagnosed with HCC.

Key Factors: The document covers various aspects of HCC management, including surveillance, diagnosis, and treatment. It emphasizes the importance of imaging and biopsy in the diagnosis and staging of HCC and provides recommendations for different treatment options based on the stage of the disease.

American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts ⁽¹¹⁾

Study Design: This guideline by the American Gastroenterological Association (AGA) provides recommendations for the management of asymptomatic neoplastic pancreatic cysts.

Target Population: Adult patients with asymptomatic pancreatic cysts identified by radiology.

Key Factors: The guideline emphasizes the importance of identifying cysts with early invasive cancer or high-grade dysplasia. It recommends MRI for surveillance and endoscopic ultrasonography with fine-needle aspiration (EUS-FNA) for cysts with high-risk features.

ACR Appropriateness Criteria® Indeterminate Renal Mass ⁽¹³⁾

Study Design: This document outlines guidelines for the evaluation of indeterminate renal masses, developed by a multidisciplinary expert panel and reviewed annually.

Target Population: Patients with indeterminate renal masses detected incidentally.

Key Factors: The guidelines recommend CT and MRI with intravenous contrast as the mainstays of evaluation. Contrast-enhanced ultrasound is also suggested as an alternative for patients with contraindications to CT or MRI contrast.

ACR Appropriateness Criteria® Hernia ⁽³⁰⁾

Study Design: This document provides evidence-based guidelines for the initial imaging of adult patients with suspected abdominopelvic hernias. The guidelines are developed by a multidisciplinary expert panel and are reviewed annually.

Target Population: Adult patients with signs or symptoms prompting suspicion of abdominopelvic hernia.

Key Factors: The document emphasizes the importance of imaging in the diagnosis and management of hernias, recommending CT and ultrasound as first-line modalities. MRI protocols may also be useful, especially in patients with orthopedic instrumentation.

ANALYSIS OF EVIDENCE

Analysis ^(1,7,11,13,30):

In summary, while all articles highlight the importance of CT imaging in diagnosing various conditions, they differ in their focus on specific conditions, imaging protocols, considerations for radiation exposure, and the use of contrast agents. Garcia et al. (2022) provide detailed appropriateness criteria for imaging hernias, Wang et al. (2020) discuss the characterization of renal masses, and Marrero et al. (2018) address the diagnosis and management of HCC. These differences reflect the unique requirements and considerations for imaging different types of abdominal conditions.

Shared Findings:

- **Importance of CT Imaging:** All articles emphasize the significance of CT imaging in diagnosing various conditions. For instance, Garcia et al. (2022) highlight the role of CT in evaluating abdominal wall hernias, while Wang et al. (2020) discuss its utility in characterizing indeterminate renal masses. Marrero et al. (2018) also underscore the importance of CT in diagnosing hepatocellular carcinoma (HCC).
- **Diagnostic Accuracy:** The articles agree on the high diagnostic accuracy of CT imaging. Garcia et al. (2022) mention the high sensitivity and positive predictive value (PPV) of CT in diagnosing hernias. Similarly, Wang et al. (2020) note the sensitivity and specificity of CT in diagnosing renal cell carcinoma (RCC). Marrero et al. (2018) also highlight the diagnostic performance of multiphase CT in evaluating HCC.
- **Role in Initial Imaging:** CT is commonly recommended as the initial imaging modality. Garcia et al. (2022) suggest CT for initial imaging of suspected abdominal wall hernias. Wang et al. (2020) recommend CT for initial imaging of indeterminate renal masses. Marrero et al. (2018) also advocate for CT in the initial diagnostic evaluation of HCC.

POLICY HISTORY

Date	Summary
July 2025	<ul style="list-style-type: none"> ● Added a Summary of Evidence and Analysis of Evidence ● Removed, “One of the following” from Suspected adrenocortical carcinoma in the Endocrine Disorders
June 2025	<ul style="list-style-type: none"> ● This guideline replaces Evolent Clinical Guideline 030 for Abdomen CT ● Purpose revised

Date	Summary
	<ul style="list-style-type: none"> ● Hernia section reorganized and revised ● Genetic and cancer sections updated ● Added in general information statement regarding guideline criteria development by reputable sources, standard of care, and best practices ● Applicable Line of Business adjusted – Medicare checked ● Updated language in the preoperative/postoperative section ● Segment added to combinations studies about if the required use of conscious sedation is needed the entire combination is indicated ● Background reduced ● References updated
June 2024	<ul style="list-style-type: none"> ● Revised the purpose ● Genetics section and Malignancy was reorganized ● Organ section was reorganized ● Fixed typo in pancreas section for mm to be cm ● Renal Bosniak section was adjusted to incorporate background into this section for further clarification ● Polycystic Kidney Disease was updated ● Known Malignancy section was adjusted to indicate initial staging, restaging, and surveillance to be consistent with new cancer bundles coming out ● Background cut ● Added in post-embolization imaging ● Added in CPT code +0722T ● Added in Contraindications and Preferred Studies Statement in Background ● Adjusted Combination section

LEGAL AND COMPLIANCE

Guideline Approval



Committee

Reviewed / Approved by Evolut Specialty Services Clinical Guideline Review Committee

Disclaimer

Evolut Clinical Guidelines do not constitute medical advice. Treating health care professionals are solely responsible for diagnosis, treatment, and medical advice. Evolut uses Clinical Guidelines in accordance with its contractual obligations to provide utilization management. Coverage for services varies for individual members according to the terms of their health care coverage or government program. Individual members' health care coverage may not utilize some Evolut Clinical Guidelines. Evolut clinical guidelines contain guidance that requires prior authorization and service limitations. A list of procedure codes, services or drugs may not be all inclusive and does not imply that a service or drug is a covered or non-covered service or drug. Evolut reserves the right to review and update this Clinical Guideline in its sole discretion. Notice of any changes shall be provided as required by applicable provider agreements and laws or regulations. Members should contact their Plan customer service representative for specific coverage information.

Evolut Clinical Guidelines are comprehensive and inclusive of various procedural applications for each service type. Our guidelines may be used to supplement Medicare criteria when such criteria is not fully established. When Medicare criteria is determined to not be fully established, we only reference the relevant portion of the corresponding Evolut Clinical Guideline that is applicable to the specific service or item requested in order to determine medical necessity.

REFERENCES

1. Francis IR, Mayo-Smith WW. Diseases of the Abdomen and Pelvis 2018-2021. In: Hodler J, ed. IDKD Springer Series; 2018:85-90. doi:10.1007/978-3-319-75019-4_9
2. Referenced with permission from the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Neuroendocrine and Adrenal Tumors Version 1.2025 © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. To view the most recent and complete version of the guideline, go online to NCCN.org.
3. Chernyak V, Horowitz JM, Kamel IR, et al. ACR Appropriateness Criteria® Liver Lesion-Initial Characterization. *Journal of the American College of Radiology*. 2020;17(11):S429-S446. doi:10.1016/j.jacr.2020.09.005
4. Referenced with permission from the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hepatocellular Carcinoma Version 1.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. To view the most recent and complete version of the guideline, go online to NCCN.org.
5. Arif-Tiwari H, Porter KK, Kamel IR, et al. ACR Appropriateness Criteria® Abnormal Liver Function Tests. *Journal of the American College of Radiology*. 2023;20(11):S302-S314. doi:10.1016/j.jacr.2023.08.023
6. Mounajjed T. Hepatocellular Adenoma and Focal Nodular Hyperplasia. *Clin Liver Dis (Hoboken)*. 2021;17(4):244-248. doi:10.1002/cld.1069
7. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology*. 2018;68(2):723-750. doi:10.1002/hep.29913
8. Catanzaro E, Gringeri E, Burra P, Gambato M. Primary Sclerosing Cholangitis-Associated Cholangiocarcinoma: From Pathogenesis to Diagnostic and Surveillance Strategies. *Cancers (Basel)*. 2023;15(20):4947. doi:10.3390/cancers15204947
9. Fábrega-Foster K, Kamel IR, Horowitz JM, et al. ACR Appropriateness Criteria® Pancreatic Cyst. *Journal of the American College of Radiology*. 2020;17(5):S198-S206. doi:10.1016/j.jacr.2020.01.021
10. Megibow AJ, Baker ME, Morgan DE, et al. Management of Incidental Pancreatic Cysts: A White Paper of the ACR Incidental Findings Committee. *Journal of the American College of Radiology*. 2017;14(7):911-923. doi:10.1016/j.jacr.2017.03.010
11. Vege SS, Ziring B, Jain R, Moayyedi P. American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. *Gastroenterology*. 2015;148(4):819-822. doi:10.1053/j.gastro.2015.01.015
12. Whitcomb DC, Buchner AM, Forsmark CE. AGA Clinical Practice Update on the Epidemiology, Evaluation, and Management of Exocrine Pancreatic Insufficiency: Expert Review. *Gastroenterology*. 2023;165(5):1292-1301. doi:10.1053/j.gastro.2023.07.007
13. Wang ZJ, Nikolaidis P, Khatri G, et al. ACR Appropriateness Criteria® Indeterminate Renal Mass. *Journal of the American College of Radiology*. 2020;17(11):S415-S428. doi:10.1016/j.jacr.2020.09.010

14. Referenced with permission from the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Kidney Cancer Version 3.2025 © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. To view the most recent and complete version of the guideline, go online to NCCN.org.
15. Herts BR, Silverman SG, Hindman NM, et al. Management of the Incidental Renal Mass on CT: A White Paper of the ACR Incidental Findings Committee. *Journal of the American College of Radiology*. 2018;15(2):264-273. doi:10.1016/j.jacr.2017.04.028
16. Campbell SC, Clark PE, Chang SS, Karam JA, Souter L, Uzzo RG. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part i. *Journal of Urology*. 2021;206(2):199-208. doi:10.1097/JU.0000000000001911
17. Richard PO, Violette PD, Bhindi B, et al. 2023 UPDATE – Canadian Urological Association guideline: Management of cystic renal lesions. *Canadian Urological Association Journal*. 2023;17(6):162-174. doi:10.5489/cuaj.8389
18. Flum AS, Hamoui N, Said MA, et al. Update on the Diagnosis and Management of Renal Angiomyolipoma. *Journal of Urology*. 2016;195(4P1):834-846. doi:10.1016/j.juro.2015.07.126
19. Ryan JW, Farrelly C, Geoghegan T. What Are the Indications for Prophylactic Embolization of Renal Angiomyolipomas? A Review of the Current Evidence in the Literature. *Canadian Association of Radiologists Journal*. 2018;69(3):236-239. doi:10.1016/j.carj.2018.01.002
20. Northrup H, Koenig MK, Pearson DA, Au KS. Tuberous Sclerosis Complex. *GeneReviews*®. Published online August 1, 2024. <https://www.ncbi.nlm.nih.gov/books/NBK1220/>
21. Chan K, Chedgy E, Bent C, Turner K. Surveillance imaging for sporadic renal angiomyolipoma less than 40 mm: lessons learnt and recommendations from the experience of a large district general hospital. *The Annals of The Royal College of Surgeons of England*. 2018;100(6):480-484. doi:10.1308/rcsann.2018.0040
22. Bardin F, Chevallier O, Bertaut A, et al. Selective arterial embolization of symptomatic and asymptomatic renal angiomyolipomas: a retrospective study of safety, outcomes and tumor size reduction. *Quant Imaging Med Surg*. 2017;7(1):8-23. doi:10.21037/qims.2017.01.02
23. Zeid M, Sayedin H, Nabi N, et al. Active Surveillance for Renal Angiomyolipoma Less Than 4 Centimeters: A Systematic Review of Cohort Studies. *Cureus*. 2022;14:e22678. doi:10.7759/cureus.22678
24. Krähling H, Seidensticker M, Heindel WL, Gerwing M. Diagnostic approach to splenic lesions. *RoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren*. 2024;196(6):573-581. doi:10.1055/a-2193-2292
25. Kim N, Auerbach A, Manning MA. Algorithmic Approach to the Splenic Lesion Based on RadiologicPathologic Correlation. *Radiographics*. 2022;42(3):683-701. doi:10.1148/rg.210071
26. Zeiger MA, Thompson GB, Duh QY, et al. American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons Medical Guidelines

- for the Management of Adrenal Incidentalomas: Executive Summary of Recommendations. *Endocrine Practice*. 2009;15(5):450-453. doi:10.4158/EP.15.5.450
27. Cartwright SL, Knudson MP. Diagnostic imaging of acute abdominal pain in adults. *Am Fam Physician*. 2015;91(7):452-459. <http://www.ncbi.nlm.nih.gov/pubmed/25884745>
 28. Porter KK, Zaheer A, Kamel IR, et al. ACR Appropriateness Criteria® Acute Pancreatitis. *Journal of the American College of Radiology*. 2019;16(11):S316-S330. doi:10.1016/j.jacr.2019.05.017
 29. Frickenstein AN, Jones MA, Behkam B, McNally LR. Imaging Inflammation and Infection in the Gastrointestinal Tract. *Int J Mol Sci*. 2019;21(1):243. doi:10.3390/ijms21010243
 30. Garcia EM, Pietryga JA, Kim DH, et al. ACR Appropriateness Criteria® Hernia. *Journal of the American College of Radiology*. 2022;19(11):S329-S340. doi:10.1016/j.jacr.2022.09.016
 31. Earle D, Roth S, Saber A, et al. Guidelines for Laparoscopic Ventral Hernia Repair. *Society of American Gastrointestinal and Endoscopic Surgeons*. Published online 2025. <https://www.sages.org/publications/guidelines/guidelines-for-laparoscopic-ventral-hernia-repair/>
 32. American College of Radiology. ACR Appropriateness Criteria® Hernia. *American College of Radiology*. Published online 2022. <https://acsearch.acr.org/docs/3158169/Narrative/>
 33. Laracca GG, Spota A, Perretta S. Optimal workup for a hiatal hernia. *Ann Laparosc Endosc Surg*. 2021;6. doi:10.21037/ALES.2020.03.02
 34. Russo GK, Zaheer A, Kamel IR, et al. ACR Appropriateness Criteria® Right Upper Quadrant Pain: 2022 Update. *Journal of the American College of Radiology*. 2023;20(5):S211-S223. doi:10.1016/j.jacr.2023.02.011
 35. Murphy DJ, Aghayev A, Steigner ML. Vascular CT and MRI: a practical guide to imaging protocols. *Insights Imaging*. 2018;9(2):215-236. doi:10.1007/s13244-018-0597-2
 36. Heller MT, Harisinghani M, Neitlich JD, Yeghiayan P, Berland LL. Managing Incidental Findings on Abdominal and Pelvic CT and MRI, Part 3: White Paper of the ACR Incidental Findings Committee II on Splenic and Nodal Findings. *Journal of the American College of Radiology*. 2013;10(11):833-839. doi:10.1016/j.jacr.2013.05.020
 37. ACR-SABI-SAR-SPR. ACR-SABI-SAR-SPR PRACTICE PARAMETER FOR THE PERFORMANCE OF COMPUTED TOMOGRAPHY (CT) OF THE ABDOMEN AND COMPUTED TOMOGRAPHY (CT) OF THE PELVIS. *American College of Radiology*. Published online 2021. Accessed February 4, 2025. <https://gravitas.acr.org/PPTS/DownloadPreviewDocument?ReleaseId=2&DocId=168>
 38. Bourgioti C, Chatoupis K, Mouloupoulos LA. Current imaging strategies for the evaluation of uterine cervical cancer. *World J Radiol*. 2016;8(4):342. doi:10.4329/wjr.v8.i4.342
 39. Referenced with permission from the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hepatocellular Carcinoma Version 4.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. To view the most recent and complete version of the guideline, go online to NCCN.org. https://www.nccn.org/professionals/physician_gls/pdf/hcc.pdf

40. Referenced with permission from the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Esophageal and Esophagogastric Junction Cancers Version 5.2024. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. To view the most recent and complete version of the guideline, go online to NCCN.org.
41. Referenced with permission from the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Melanoma: Uveal Version 1.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. To view the most recent and complete version of the guideline, go online to NCCN.org.
42. Referenced with permission from the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Ampullary Adenocarcinoma Version 2.2025. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. To view the most recent and complete version of the guideline, go online to NCCN.org.
43. Referenced with permission from the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Pancreatic Adenocarcinoma Version 2.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. To view the most recent and complete version of the guideline, go online to NCCN.org.
44. Farsad K, Kolbeck KJ. Clinical and Radiologic Evaluation of Patients Before TIPS Creation. *American Journal of Roentgenology*. 2014;203(4):739-745. doi:10.2214/AJR.14.12999
45. Scheirey CD, Fowler KJ, Therrien JA, et al. ACR Appropriateness Criteria® Acute Nonlocalized Abdominal Pain. *Journal of the American College of Radiology*. 2018;15(11):S217-S231. doi:10.1016/j.jacr.2018.09.010
46. Harris P, Torres V. Polycystic Kidney Disease, Autosomal Dominant. *GeneReviews*®. Published online September 29, 2022. <https://www.ncbi.nlm.nih.gov/books/NBK1246/>
47. Gansevoort RT, Arici M, Benzing T, et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: A position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. *Nephrology Dialysis Transplantation*. 2016;31(3):337-348. doi:10.1093/ndt/gfv456
48. Referenced with permission from the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate Version 3.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. To view the most recent and complete version of the guideline, go online to NCCN.org.
49. Pilarski R, Byrne L, Carlo MI, Hanson H, Cebulla C, Abdel-Rahman M. BAP1 Tumor Predisposition Syndrome. *GeneReviews*®. Published online December 5, 2024. <https://www.ncbi.nlm.nih.gov/books/NBK390611/>
50. Shuman C, Kalish JM, Weksberg R. Beckwith-Wiedemann Syndrome. *GeneReviews*®. Published online September 21, 2023. <https://www.ncbi.nlm.nih.gov/books/NBK1394/>

51. Langer AL. Beta-Thalassemia. *GeneReviews*®. Published online February 8, 2024. <https://www.ncbi.nlm.nih.gov/books/NBK1426/>
52. Sattler EC, Steinlein OK. Birt-Hogg-Dubé Syndrome. *GeneReviews*®. Published online December 5, 2024. <https://www.ncbi.nlm.nih.gov/books/NBK1522/>
53. Referenced with permission from the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate Version 2.2025 © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. To view the most recent and complete version of the guideline, go online to NCCN.org.
54. Hughes DA, Pastores GM. Gaucher Disease. *GeneReviews*®. Published online December 7, 2023. <https://www.ncbi.nlm.nih.gov/books/NBK1269/>
55. Piperno A, Bertola F, Bentivegna A. Juvenile Hemochromatosis. *GeneReviews*®. Published online January 9, 2020. <https://www.ncbi.nlm.nih.gov/books/NBK1170/>
56. Kamihara J, Schultz KA, Rana HQ. FH Tumor Predisposition Syndrome. *GeneReviews*®. Published online May 8, 2025. <https://www.ncbi.nlm.nih.gov/books/NBK1252/>
57. Referenced with permission from the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Neuroendocrine and Adrenal Tumors Version 5.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. To view the most recent and complete version of the guideline, go online to NCCN.org. https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf
58. Giusti F, Marini F, Brandi ML. Multiple Endocrine Neoplasia Type 1. *GeneReviews*®. Published online March 10, 2022. <https://www.ncbi.nlm.nih.gov/books/NBK1538/>
59. Eng C, Plitt G. Multiple Endocrine Neoplasia Type 2. *GeneReviews*®. Published online August 10, 2023. <https://www.ncbi.nlm.nih.gov/books/NBK1257/>
60. Else T, Greenberg S, Fishbein L. Hereditary Paraganglioma-Pheochromocytoma Syndromes. *GeneReviews*®. Published online September 21, 2023. <https://www.ncbi.nlm.nih.gov/books/NBK1548/>
61. Yehia L, Eng C. PTEN Hamartoma Tumor Syndrome. *GeneReviews*®. Published online February 11, 2021. <https://www.ncbi.nlm.nih.gov/books/NBK1488/>
62. Bender M, Carlberg K. Sickle Cell Disease. *GeneReviews*®. Published online February 13, 2025. <https://www.ncbi.nlm.nih.gov/books/NBK1377/>
63. McGarrity TJ, Amos CI, Baker MJ. Peutz-Jeghers Syndrome. *GeneReviews*®. Published online September 2, 2021. <https://www.ncbi.nlm.nih.gov/books/NBK1266/>
64. van Leeuwen RS van, Ahmad S, van Nesselrooij B, Zandee W, Giles RH. Von Hippel-Lindau Syndrome. *GeneReviews*®. Published online May 1, 2025. <https://www.ncbi.nlm.nih.gov/books/NBK1463/>
65. Watanabe R, Hashimoto M. Eosinophilic Granulomatosis with Polyangiitis: Latest Findings and Updated Treatment Recommendations. *J Clin Med*. 2023;12(18). doi:10.3390/jcm12185996
66. Kim SP, Cohalan C, Kopek N, Enger SA. A guide to 90Y radioembolization and its dosimetry. *Physica Medica*. 2019;68:132-145. doi:10.1016/j.ejmp.2019.09.236

